Literature DB >> 17599293

[Prevalence of hepatitis C virus infection in Slovakia].

I Schréter1, P Kristian, C Klement, D Kohútová, P Jarcuska, L Madarová, M Avdicová, E Máderová.   

Abstract

OBJECTIVE: To assess the prevalence of hepatitis C in the general Slovak population without any further evaluation or risk group stratification.
MATERIAL AND METHODS: A total of 3,608 remnant serum specimens from epidemiological surveys in 1997 (1,484 specimens) and 2002 (2,124) were analyzed. These were from randomly selected persons over 15 years of age from all over Slovakia. The anti-HCV antibodies were detected using the 4th generation ELISA test. In case of positive or borderline results, the presence of HCV RNA was determined qualitatively.
RESULTS: Of the 3,608 analyzed specimens, 55 (1.52 %) were anti-HCV-positive and 10 (0.28 %) were borderline positive. HCV RNA was detected in 24 cases (0.67 %). A comparison of the 1997 and 2002 results showed a statistically significant (p < 0.01) increase of anti-HCV-positive specimens. A similar--but not significant--increase was noted in HCV RNA-positive cases. Despite a slightly higher prevalence of HCV infection in females, no statistically significant gender differences were found. Whereas anti-HCV positivity increased slightly with age, most HCV RNA patients were from the middle age group, i.e. between 36 and 45 years of age. The geographic distribution of HCV cases across Slovakia was relatively even.
CONCLUSIONS: The prevalence of anti-HCV antibodies in subjects representing the general population of Slovakia older than 15 years was 1.52 %; chronic HCV infection was confirmed in 0.67 % of cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599293

Source DB:  PubMed          Journal:  Klin Mikrobiol Infekc Lek        ISSN: 1211-264X


  7 in total

1.  Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.

Authors:  Roman Chlibek; Jan Smetana; Renata Sosovickova; Peter Gal; Petr Dite; Vlasta Stepanova; Lenka Pliskova; Stanislav Plisek
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

2.  Prevalence and Risk Factors for Hepatitis B Virus Infection in Roma and Non-Roma People in Slovakia.

Authors:  Sylvia Drazilova; Martin Janicko; Pavol Kristian; Ivan Schreter; Monika Halanova; Ingrid Urbancikova; Andrea Madarasova-Geckova; Maria Marekova; Daniel Pella; Peter Jarcuska
Journal:  Int J Environ Res Public Health       Date:  2018-05-22       Impact factor: 3.390

3.  How close are we to hepatitis C virus elimination in Central Europe?

Authors:  Robert Flisiak; Sona Frankova; Ivica Grgurevic; Bela Hunyady; Peter Jarcuska; Limas Kupčinskas; Michael Makara; Marieta Simonova; Jan Sperl; Ieva Tolmane; Adriana Vince; Dorota Zarębska-Michaluk
Journal:  Clin Exp Hepatol       Date:  2020-02-17

Review 4.  Epidemiology of HCV infection in the Central European region.

Authors:  Petr Urbánek; Pavol Kristian; Michael Makara; Bela Hunyady; Krzysztof Tomasiewicz
Journal:  Clin Exp Hepatol       Date:  2016-03-24

Review 5.  New therapeutic options for HCV in Central Europe.

Authors:  Robert Flisiak; Petr Urbánek; Laszlo Rokusz; Marian Oltman; Mihaly Makara; Martin Janicko
Journal:  Clin Exp Hepatol       Date:  2016-03-24

Review 6.  Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.

Authors:  S H I Hofstraat; A M Falla; E F Duffell; S J M Hahné; A J Amato-Gauci; I K Veldhuijzen; L Tavoschi
Journal:  Epidemiol Infect       Date:  2017-09-11       Impact factor: 2.451

7.  Hepatitis C virus antibodies in outpatients with chronic kidney disease.

Authors:  Lubomir Skladany; Daniela Janceková; Juraj Svac
Journal:  Clin Exp Hepatol       Date:  2018-12-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.